Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Conditions

• Prostate Cancer

Interventions

• BIOLOGICAL: 2mg INO-5150 and electroporation device CELLECTRA®-5P
• BIOLOGICAL: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
• BIOLOGICAL: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
• BIOLOGICAL: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
• DEVICE: Electroporation using CELLECTRA®-5P

Sponsor

Inovio Pharmaceuticals